1-[2-(4-tert-Butyl-phenoxy)-ethyl]-piperidine | 53669-79-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-[2-(4-tert-Butyl-phenoxy)-ethyl]-piperidine
• 英文别名: 1-[2-(4-Tert-butylphenoxy)ethyl]piperidine
• CAS: 53669-79-7
• 化学式: C₁₇H₂₇NO
• 分子量: 261.407
• InChiKey: OXDMGSINDGYSSU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof
  申请人：Unoki Gen

  公开号：US20070173519A1

  公开（公告）日：2007-07-26

  A pyrazolopyrimidine derivative represented by formula (1) and pharmaceutically acceptable salt thereof exhibit excellent inhibitory activity against MAPKAP-K2. Accordingly, medicines containing this compound as an active ingredient are expected to be effective for treating diseases mediated by MAPKAP-K2 such as, for example, inflammatory disorder, autoimmune diseases, destructive osteopathy, cancer and/or tumor growth.

  由式（1）表示的吡唑吡嘧啶衍生物及其药用盐对MAPKAP-K2表现出优异的抑制活性。因此，含有该化合物作为活性成分的药物预计对治疗由MAPKAP-K2介导的疾病，如炎症性疾病、自身免疫疾病、破坏性骨病、癌症和/或肿瘤生长等方面具有有效性。
• PROCESSES AND INTERMEDIATES FOR PREPARING INDOLE PHARMACEUTICALS
  申请人：INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION

  公开号：US20160107991A1

  公开（公告）日：2016-04-21

  The invention described herein pertains to processes and intermediates for preparing indole containing pharmaceuticals, particularly to processes and intermediates for preparing selective estrogen receptor modulators, such as bazedoxifene.

  本发明涉及制备含有吲哚类药物的过程和中间体，特别是制备选择性雌激素受体调节剂（如巴泽度芬）的过程和中间体。
• Pyrazolopyrimidine Derivatives or Pharmaceutically Acceptable Salts Thereof
  申请人：UNOKI Gen

  公开号：US20090054472A1

  公开（公告）日：2009-02-26

  A pyrazolopyrimidine derivative represented by formula (1) and pharmaceutically acceptable salt thereof exhibit excellent inhibitory activity against MAPKAP-K2. Accordingly, medicines containing this compound as an active ingredient are expected to be effective for treating diseases mediated by MAPKAP-K2 such as, for example, inflammatory disorder, autoimmune diseases, destructive osteopathy, cancer and/or tumor growth.

  式（1）所表示的吡唑并嘧啶衍生物及其药学上可接受的盐，表现出对MAPKAP-K2的优异抑制活性。因此，含有该化合物作为活性成分的药物预计将对由MAPKAP-K2介导的疾病具有治疗作用，例如，炎症性疾病、自身免疫性疾病、破坏性骨病、癌症和/或肿瘤生长。
• INHIBITORS OF THE BMP SIGNALING PATHWAY
  申请人：Yu Paul B.

  公开号：US20110053930A1

  公开（公告）日：2011-03-03

  The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation.

  本发明提供了BMP信号通路的小分子抑制剂。这些化合物可以用于调节细胞生长、分化、增殖和凋亡，因此可能有用于治疗与BMP信号通路相关的疾病或病症，包括炎症、心血管疾病、血液疾病、癌症和骨骼疾病，以及调节细胞分化和/或增殖。
• Inhibitors of VEGF Receptor and HGF Receptor Signalling
  申请人：Vaisburg Arkadii

  公开号：US20100216766A1

  公开（公告）日：2010-08-26

  The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions

  本发明涉及抑制VEGF受体信号和HGF受体信号的方法。本发明提供了抑制VEGF受体信号和HGF受体信号的化合物和方法。本发明还提供了治疗细胞增殖性疾病和病症的组合物和方法。